Trial Profile

A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veliparib (Primary) ; Bendamustine; Rituximab
Indications Chronic lymphocytic leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Therapeutic Use

17 Mar 2017 Results evaluating the safety, tolerability, and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
08 Dec 2015 Results (n=15) from Phase 1b and Cohort Expansion part of the study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com